BibTex format
@article{Liseth:2026:10.1126/sciadv.aef5331,
author = {Liseth, O and Appleton, E and Kendall, B and Thompson, J and Sangsuwannukul, T and Tonne, J and Diaz, RM and Evgin, L and Patrikeev, A and Sarbia, N and Foo, S and Harrington, K and Ono, M and Melcher, A and Vile, R},
doi = {10.1126/sciadv.aef5331},
journal = {Sci Adv},
title = {Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity.},
url = {http://dx.doi.org/10.1126/sciadv.aef5331},
volume = {12},
year = {2026}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Chimeric antigen receptor (CAR) T cell therapy faces many challenges against solid tumors including T cell exhaustion and poor CAR durability. Here, we show that engaging the CAR T cell endogenous T cell receptor (TCR) using an oncolytic virus enhances CAR T cell functionality, durability, and therapy. Upon combination therapy of solid tumors with CAR T cells and vesicular stomatitis virus (VSV), a subpopulation of antiviral, TCR-primed CAR T cells was generated with enhanced effector functions, altered activation states, and differential gene and protein expression when compared to non-TCR-primed CAR T cells. Single-cell RNA sequencing showed clonal expansion of anti-VSV CAR T cells and enhancement of effector-associated genes with VSV-mediated CAR T cell expansion. CD4 T cells played a pivotal role in the development of these TCR-primed CAR T cells. These results provide a strong rationale both for a novel use of systemic oncolytic virotherapy and for directly exploiting the CAR T cell TCR to fine tune the CAR T cell phenotype and function.
AU - Liseth,O
AU - Appleton,E
AU - Kendall,B
AU - Thompson,J
AU - Sangsuwannukul,T
AU - Tonne,J
AU - Diaz,RM
AU - Evgin,L
AU - Patrikeev,A
AU - Sarbia,N
AU - Foo,S
AU - Harrington,K
AU - Ono,M
AU - Melcher,A
AU - Vile,R
DO - 10.1126/sciadv.aef5331
PY - 2026///
TI - Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity.
T2 - Sci Adv
UR - http://dx.doi.org/10.1126/sciadv.aef5331
UR - https://www.ncbi.nlm.nih.gov/pubmed/42247513
VL - 12
ER -